论文部分内容阅读
目的:评价注射用唑来磷酸治疗恶性肿瘤转移性骨痛的有效性和安全性。方法:共入选病例56例,其中治疗组28例,对照组28例,采用随机双盲双模阳性药博宁平行对照研究方法,治疗组,唑来磷酸4mg+生理盐水50mL静脉滴注,15min。对照组,博宁90mg+生理盐水500mL静脉滴注4h,观察28d为1个疗程。观察用药患者的疗效和毒副反应。结果:治疗后28d评价疗效,试验组有效率93%,对照组有效率71%,疗效差异无显著性(P>0.05);主要毒副反应试验组与对照组差异无显著性(P>0.05)。结论:唑来磷酸对癌性骨转移性疼痛有较好的临床疗效和安全性,在同类治疗药物中具有使用更方便的优势
Objective: To evaluate the efficacy and safety of zoledronic acid for the treatment of metastatic bone pain in malignant tumors. Methods: A total of 56 cases were enrolled in this study. Among them, 28 cases in the treatment group and 28 cases in the control group were treated with a randomized, double-blind, double-modality, Bonnin parallel study. The patients in the treatment group were treated with 4 mg of zoledronic acid and 50 mL of saline for 15 minutes. The control group, Bonin 90mg + saline 500mL intravenous infusion 4h, observation 28d for a course of treatment. Observed the efficacy and side effects of drug treatment. Results: The curative effect was evaluated on the 28th day after treatment. The effective rate was 93% in the experimental group and 71% in the control group, with no significant difference in the curative effect (P> 0.05). There was no significant difference between the major toxicities test group and the control group (P> 0.05 ). Conclusion: Zoledronic acid has good clinical efficacy and safety for cancerous bone metastases, and has the advantage of being more convenient to use in the same kind of therapeutic drugs